Abstract
Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma (MEL): 3-year landmark analysis of a randomized phase 2 trial
Pigment cell and melanoma research, Vol.33(1), pp.160-160
01/2020
Abstract
THE 16TH INTERNATIONAL CONGRESS OF THE SOCIETY FOR MELANOMA RESEARCH
abstract only
Details
- Title: Subtitle
- Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma (MEL): 3-year landmark analysis of a randomized phase 2 trial
- Creators
- Jason ChesneyIgor PuzanovFrances CollichioParminder SinghMohammed M Milhem - University of Iowa, Internal MedicineJohn GlaspyOmid HamidMerrick I RossPhilip FriedlanderClaus GarbeTheodore LoganAxel HauschildCéleste LebbéMin Yi - AmgenANjali SharmaJanice Mehnert
- Resource Type
- Abstract
- Publication Details
- Pigment cell and melanoma research, Vol.33(1), pp.160-160
- ISSN
- 1755-1471
- eISSN
- 1755-148X
- Number of pages
- 108
- Comment
- THE 16TH INTERNATIONAL CONGRESS OF THE SOCIETY FOR MELANOMA RESEARCH. Abstracts. DOI:10.1111/pcmr.12834. Pigment Cell & Melanoma Research, Volume 33, Issue 1 p. 148-255.
- Language
- English
- Date published
- 01/2020
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984183992402771
Metrics
16 Record Views